For people with chronic lung disease, infection with nontuberculous mycobacteria, or NTM, can mean years of difficult treatment. Patients typically take several antibiotics for long stretches, and many still feel ill because of persistent inflammation. Steroids, the obvious tool for quieting inflammation, have largely been off the table for fear of weakening the immune defenses that keep the bacteria in check.
New laboratory research from Trinity College Dublin and St. James’s Hospital suggests that fear may be overstated. In human immune cells infected with Mycobacterium avium, one of the most common causes of NTM lung disease, the steroid dexamethasone sharply reduced inflammation without letting the bacteria grow. The study is published in the Journal of Infectious Diseases.
A Growing Problem
NTM infections are rising worldwide, and the Mycobacterium avium complex is a leading culprit. Even while antibiotics are doing their job, chronic inflammation can drive symptoms, damage tissue and erode quality of life. Clinicians have long worried that suppressing the immune response with steroids would undermine the body’s ability to fight the infection, particularly its T cell responses.
“Current treatment strategies for NTM disease focus primarily on killing the bacteria,” said Dr Donal Cox of the Trinity Translational Medicine Institute, the study’s senior author. Because inflammation itself contributes to symptoms and tissue damage, he said, controlling it without impairing the body’s antimicrobial immunity could open the door to more effective therapies.
Inside the Macrophage
The team studied primary human macrophages, the frontline immune cells that engulf invading bacteria, as they responded to M. avium. The researchers focused on cell metabolism, which shapes how macrophages react to infection. That link has been studied extensively in tuberculosis but much less in NTM disease. The group had previously shown that dexamethasone alters the metabolism of macrophages infected with M. tuberculosis, and they wanted to know whether the same levers could be pulled in M. avium infection.
Dexamethasone significantly reduced the surge in metabolic activity that infection drove in the macrophages. It also markedly lowered production of the inflammatory signaling molecules TNF, IL-1ฮฒ, IL-6 and IL-8. Crucially, treated macrophages kept their ability to control the bacteria, and bacterial growth inside them did not increase.
The authors conclude that in human macrophages, the inflammatory response can be separated from bacterial control.
Metabolism and Defense
Professor Joseph Keane, Professor of Medicine at Trinity, highlighted the role of glycolysis, a core energy-producing pathway, in how macrophages respond to NTM. The metabolic shift toward glycolysis is enough to drive the cells’ antimicrobial activity, he said, but it is not required for it. In his view, the data support developing steroids as adjuvant therapies used alongside antibiotics.
Early Days
The work is a laboratory study in cultured human cells, and the authors say further research is needed. The announcement does not report sample sizes, doses or statistical results, and no animal or clinical data are described. The researchers say their use of primary human cells and real-time metabolic measurements makes them hopeful the findings will translate, and that the results justify investigating steroids as host-directed therapies to pair with existing antimicrobials. The study was funded by the Royal City of Dublin Hospital Trust.
Featured image: Mycobacteria under the microscope (M. tuberculosis, a relative of M. avium, shown). Scientific Inquirer media library. (The press release did not include an image.)
Endnotes
- Cox, D., et al. Journal of Infectious Diseases, 2026. DOI: 10.1093/infdis/jiag394.
- Trinity College Dublin. “Trinity research shows steroids reduce inflammation in chronic mycobacterial lung infections without limiting antimicrobial defence.” EurekAlert!, 11 August 2026. https://www.eurekalert.org/news-releases/1139280




Leave a Reply